Aligos Therapeutics (ALGS) announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus, HBV, infection. The first protocol defined interim analysis includes approximately 60% HBeAg- participants that complete 12 weeks of the treatment period. This enrollment milestone occurred in Q4 2025. In addition, the planned enrollment of this cohort of 60 HBeAg- participants completed in January 2026. The first interim analysis is expected to occur in the first half of 2026. A second protocol defined interim analysis is planned when approximately 50% HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026. This interim analysis is expected to occur in the second half of 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics management to meet virtually with Piper Sandler
- Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
- Aligos Therapeutics appoints James Hassard as EVP, CCO
- Aligos Therapeutics initiated with a Buy at UBS
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule